Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open Label, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.3 mg Ranibizumab Given Monthly Compared to a TReat and EXtend Protocol in Patients With Diabetic Macular Edema

NCT01934556 is registered in ClinicalTrials.gov with Palmetto Retina Center, LLC as lead sponsor.

NCT NCT01934556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01934556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open Label, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.3 mg Ranibizumab Given Monthly Compared to a TReat and EXtend Protocol in Patients With Diabetic Macular Edema
Lead sponsor
Palmetto Retina Center, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2013
Completion date
April 30, 2018
Enrollment
150 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema